Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00402545 · ClinicalTrials.gov registry record · Phase 1

C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck

A Phase 1 study of Head and Neck Neoplasms, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target
1
Study location

NCT00402545: Completed Phase 1 study of Head and Neck Neoplasms, sponsored by Dana-Farber Cancer Institute.

NCT00402545 is a Phase 1 study of Head and Neck Neoplasms that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 29 participants, below the 264-participant average among 23 other Head and Neck Neoplasms trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00402545, a Phase 1 study of Head and Neck Neoplasms, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to determine the safest and most effective dose of 5-FU that can be given with docetaxel (Taxotere), Cisplatin and cetuximab to patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. We will also be studying the toxicity of this regimen of 4 drugs and the tumor response.

Conditions Studied

Head and Neck Neoplasms

Interventions

  • DRUG Docetaxel
  • DRUG Cisplatin
  • DRUG Cetuximab
  • DRUG 5-Fluorouracil

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2007-01
Est. Completion 2009-07
Phase Phase 1
Dana-Farber Cancer Institute

781 total trials

What the finished NCT00402545 record still lists

NCT00402545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 264-participant average among 23 other Head and Neck Neoplasms trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Head and Neck Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.

NCT00402545 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00402545 about?

NCT00402545 is a clinical study titled "C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck". The purpose of this research study is to determine the safest and most effective dose of 5-FU that can be given with docetaxel (Taxotere), Cisplatin and cetuximab to patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. We will also be studying the toxicity of ...

What is the current status of trial NCT00402545?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2007-01. Estimated completion is 2009-07.

What conditions does trial NCT00402545 study?

This clinical trial studies the following conditions: Head and Neck Neoplasms.

What interventions are being tested in trial NCT00402545?

The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Cetuximab (DRUG), 5-Fluorouracil (DRUG).

Who is sponsoring clinical trial NCT00402545?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00402545 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00402545's enrollment target sits among peer trials

29 20th of 23 higher than 4 of 23 other Head and Neck Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00402545, the US trial registry maintained by the National Library of Medicine. NCT00402545 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.